which glp 1 agonists have cardiovascular benefit GLP-1 receptor and outcome trials: An update It's important to study the
Description
GLP-1, says Kunal Shah, MD, an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center
Exenatide Activates the APPL1-AMPK-PPAR Axis to Prevent Diabetic Cardiomyocyte Apoptosis
Insulin and insulin-like growth factor 1 (IGF-1) are thought to play a role in promoting this condition, as their receptors are present on keratinocytes and fibroblasts
The SELECT trial has shown reduction in major adverse cardiovascular events
GLP-1R agonists have been extensively used in animal models of skeletal fragility
